Eagle Pharmaceuticals
EGRX
$4.75
Share price
3.94%
Change (1 day)
-83.72%
Change (1 year)
Categories
Eagle Pharmaceuticals (EGRX) - Total debt
Total debt on the balance sheet as of June 2023 : $71.61 M
According to Eagle Pharmaceuticals 's latest financial reports the company's total debt is $71.61 M. A company’s total debt is the sum of all current and non-current debts.
Eagle Pharmaceuticals - Total debt on balance sheet (from 2013 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $64 M | 137.78% |
| 2021-12-31 | $26.91 M | -21.43% |
| 2020-12-31 | $34.25 M | -17.56% |
| 2019-12-31 | $41.55 M | -6.41% |
| 2018-12-31 | $44.4 M | -7.06% |
| 2017-12-31 | $47.78 M | |
| 2013-09-30 | $N/A | -100% |
| 2012-09-30 | $8.57 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $33.63 B | 46,862.23% | 🇺🇸 USA |
 Novartis NVS | $27.28 B | 37,998.16% | 🇨🇭 Switzerland |
 Eli Lilly LLY | $26.21 B | 36,500.43% | 🇺🇸 USA |
 Amgen AMGN | $64.61 B | 90,122.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $57.40 B | 80,063.37% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $22.45 B | 31,260.75% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $20.15 B | 28,040.75% | 🇮🇱 Israel |